Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade ; volume:15 ; number:1 ; day:14 ; month:10 ; year:2024 ; pages:1-19 ; date:12.2024
Nature Communications ; 15, Heft 1 (14.10.2024), 1-19, 12.2024
- Creator
-
Bergeron, Paul
Dos Santos, Morgane
Sitterle, Lisa
Tarlet, Georges
Lavigne, Jeremy
Liu, Winchygn
Gerbé de Thoré, Marine
Clémenson, Céline
Meziani, Lydia
Schott, Cathyanne
Mazzaschi, Giulia
Berthelot, Kevin
Benadjaoud, Mohamed Amine
Milliat, Fabien
Deutsch, Eric
Mondini, Michele
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-53015-9
- URN
-
urn:nbn:de:101:1-2501012101583.691005030475
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bergeron, Paul
- Dos Santos, Morgane
- Sitterle, Lisa
- Tarlet, Georges
- Lavigne, Jeremy
- Liu, Winchygn
- Gerbé de Thoré, Marine
- Clémenson, Céline
- Meziani, Lydia
- Schott, Cathyanne
- Mazzaschi, Giulia
- Berthelot, Kevin
- Benadjaoud, Mohamed Amine
- Milliat, Fabien
- Deutsch, Eric
- Mondini, Michele
- SpringerLink (Online service)
Other Objects (12)
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Die Blockade des CXCR2/CXCL2 Signalweges als therapeutischer Ansatz im Glioblastoma multiforme
Homogenous social groups
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Homogenous denumerable Markov processes
Ionizing solvents
Homogenous Social Groups Facilitate Exchange
Schur-Convex Homogenous Difference Equations
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Die Blockade des CXCR2/CXCL2 Signalweges als therapeutischer Ansatz im Glioblastoma multiforme
Homogenous social groups
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Homogenous denumerable Markov processes
Ionizing solvents
Homogenous Social Groups Facilitate Exchange
Schur-Convex Homogenous Difference Equations
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Die Blockade des CXCR2/CXCL2 Signalweges als therapeutischer Ansatz im Glioblastoma multiforme
Homogenous social groups
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Homogenous denumerable Markov processes
Ionizing solvents
Homogenous Social Groups Facilitate Exchange
Schur-Convex Homogenous Difference Equations
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment